Want to see LKFT full AI Analyst Report?
Top Page
Lakefront Biotherapeutics
(NASDAQ:LKFT)
Select Model
Select Model
Rating:69Neutral
Price Target:
$34.00
▲(16.60% Upside)
Action:Reiterated
Date:09/09/26
The score is driven primarily by strong financial positioning (very strong balance sheet and solid reported profitability), offset by persistent negative operating/free cash flow that raises execution risk. Valuation is a positive (very low P/E), while technical indicators are broadly neutral and do not add strong support.
Positive Factors
Very strong balance sheet
Minimal leverage and a large equity base provide substantial financial flexibility for a biotechnology company pursuing clinical development and strategic transactions. This balance-sheet strength can help fund operations, absorb setbacks, and preserve options without relying heavily on external financing.
Negative Factors
Persistent cash burn
Negative operating and free cash flow despite reported profits raises questions about earnings conversion and the durability of internal cash generation. Continued cash consumption increases execution risk and makes future investment plans more dependent on the existing balance sheet.
Read all positive and negative factors
Positive Factors
Negative Factors
Very strong balance sheet
Minimal leverage and a large equity base provide substantial financial flexibility for a biotechnology company pursuing clinical development and strategic transactions. This balance-sheet strength can help fund operations, absorb setbacks, and preserve options without relying heavily on external financing.
Read all positive factors
Lakefront Biotherapeutics (LKFT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.95B
Dividend YieldN/A
Average Volume (3M)314.92K
Price to Earnings (P/E)2.9
Beta (1Y)0.65
Revenue Growth285.48%
EPS GrowthN/A
CountryUS
Employees452
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)9.05
Shares Outstanding65,897,070
10 Day Avg. Volume317,746
30 Day Avg. Volume314,919
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.65
P/FCF Ratio-6.76
Enterprise Value/Market Cap-0.23
Enterprise Value/Revenue-0.46
Enterprise Value/Gross Profit-0.48
Enterprise Value/Ebitda-0.84
Forecast
1Y Price Target
$35.50Price Target Upside21.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.94
Revenue Forecast (FY)$32.33M
Lakefront Biotherapeutics Business Overview & Revenue Model
Company Description
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in ...
Lakefront Biotherapeutics Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 12, 2026
Earnings Call Sentiment Positive
The call highlights a major strategic transformation with a high‑profile Ouro/Gilead transaction that brings a promising clinical asset (gamgertamig) and unlocks substantial financial flexibility. Operationally, the company reported meaningful quarterly improvement in operating loss and a net profit driven by financial gains, maintained a strong cash position, and emphasized cost discipline and capital‑efficient development plans. Offsetting these positives are a very large near‑term cash deployment (upfront and wind‑down costs), a steep YoY revenue decline driven by prior‑year accounting recognition, continued operating losses, and clinical and competitive risks inherent to the BCMA/CD3 space. On balance, the strategic upside and improved reported results outweigh the near‑term financial outflows and risks.Positive Updates
Strategic Partnership and Acquisition (Ouro/Gilead)
Entered into a binding agreement with Gilead for the Ouro Medicines portfolio, centered on gamgertamig (BCMA/CD3 T‑cell engager). Transaction includes an upfront payment of approximately EUR 713 million and adds 3 preclinical programs. The deal also includes a partial waiver/modification of legacy OLCA terms enhancing strategic flexibility.
Negative Updates
Sharp Revenue Decline Year‑over‑Year
Total net revenues fell to EUR 6.5 million in Q1 2026 from EUR 75.0 million in Q1 2025 — a decline of EUR 68.5 million (≈91.3% YoY). The drop was driven by the absence of prior‑year OLCA revenue recognition (EUR 57.6 million) and full release of deferred OLCA income at year‑end 2025.
Read all updates
Q1-2026 Updates
Positive
Negative
Strategic Partnership and Acquisition (Ouro/Gilead)
Entered into a binding agreement with Gilead for the Ouro Medicines portfolio, centered on gamgertamig (BCMA/CD3 T‑cell engager). Transaction includes an upfront payment of approximately EUR 713 million and adds 3 preclinical programs. The deal also includes a partial waiver/modification of legacy OLCA terms enhancing strategic flexibility.
Read all positive updates
Company Guidance
Guidance for 2026 centers on the planned close of the Ouro transaction in Q2 and the related cash outlook: the company expects to incur EUR 60–75m of Ouro-related cash expenditures (operating costs and transaction expenses) in 2026 and, together with an upfront payment of ~EUR 713m, to spend EUR 775–790m total on Ouro in 2026. Management also expects one‑time cash costs of EUR 125–175m to wind down cell therapy activities, and inclusive of Ouro and the wind‑down now forecasts year‑end cash and cash equivalents of EUR 1.975–2.05 billion. For context, cash and financial investments were EUR 2,982.2m on March 31, 2026 (versus EUR 3,297m on March 31, 2025), Q1 revenues were EUR 6.5m (EUR 4.9m supply revenue, EUR 1.6m collaboration revenue) versus EUR 75m in Q1 2025, R&D was EUR 31m, operating loss improved to EUR 63.7m (vs. EUR 158.7m a year ago, which included EUR 111m restructuring), net financial income was EUR 77.7m (including ~EUR 64.3m unrealized FX gains) driving a Q1 net profit of EUR 14.5m (vs. a EUR 153.4m loss in Q1 2025). The company also highlighted that the revised OLCA terms unlock a EUR 500m commitment for broader use (up to EUR 150m of which may be used for return of capital), received shareholder approval for a share repurchase program, and said it will retain a majority of its cash after estimated R&D spend on gamgertamig through first approval.Lakefront Biotherapeutics Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
92
Very Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 990.58M | 1.11B | 275.65M | 239.72M | 241.25M | 484.85M |
| Gross Profit | 939.84M | 1.08B | 240.79M | 239.72M | 241.25M | 483.22M |
| EBITDA | 536.41M | 358.96M | 43.33M | 51.04M | 3.87M | -100.93M |
| Net Income | 596.63M | 320.88M | 74.08M | 211.70M | -217.99M | -125.42M |
Balance Sheet | ||||||
| Total Assets | 3.35B | 3.41B | 4.14B | 4.36B | 4.73B | 5.19B |
| Cash, Cash Equivalents and Short-Term Investments | 2.24B | 3.00B | 3.12B | 3.68B | 4.09B | 4.70B |
| Total Debt | 6.36M | 6.92M | 11.72M | 9.60M | 21.90M | 26.86M |
| Total Liabilities | 87.52M | 170.65M | 1.24B | 1.56B | 2.21B | 2.55B |
| Stockholders Equity | 3.25B | 3.24B | 2.90B | 2.80B | 2.53B | 2.64B |
Cash Flow | ||||||
| Free Cash Flow | -197.40M | -271.31M | -402.14M | -425.24M | -537.49M | -561.71M |
| Operating Cash Flow | -192.82M | -257.46M | -320.03M | -405.97M | -500.54M | -503.83M |
| Investing Cash Flow | 190.86M | 288.81M | 220.60M | 71.19M | -1.25B | 541.24M |
| Financing Cash Flow | -2.17M | -3.27M | -4.92M | -5.00M | -1.49M | -3.88M |
Lakefront Biotherapeutics Technical Analysis
Positive
29.16
Price Trends
28.53
Positive
28.63
Positive
30.07
Negative
Market Momentum
0.30
Positive
53.33
Neutral
64.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LKFT, the sentiment is Positive. The current price of 29.16 is below the 20-day moving average (MA) of 29.40, above the 50-day MA of 28.53, and below the 200-day MA of 30.07, indicating a neutral trend. The MACD of 0.30 indicates Positive momentum. The RSI at 53.33 is Neutral, neither overbought nor oversold. The STOCH value of 64.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LKFT.
Lakefront Biotherapeutics Risk Analysis
Lakefront Biotherapeutics disclosed 79 risk factors in its most recent earnings report. Lakefront Biotherapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We are dependent on the transfer of the Jyseleca business, including the European and UK Marketing Authorizations, the commercial, medical affairs and development activities for Jyseleca and approximately 400 Galapagos positions in 14 European countries, to Alfasigma. Q4, 2023
2.
Risks associated to the legal uncertainty around the Unitary patent court in Europe Q4, 2023
3.
If approved, our investigational products regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway. Q4, 2023
Lakefront Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $1.95B | 2.93 | 19.58% | ― | 285.48% | ― | |
57 Neutral | $1.86B | -11.54 | -28.66% | ― | -28.56% | 10.25% | |
57 Neutral | $1.91B | -6.11 | -29.99% | ― | 1495.93% | 53.66% | |
56 Neutral | $1.86B | -31.86 | -10.06% | ― | 600.89% | 47.33% | |
54 Neutral | $1.81B | -12.54 | -72.07% | ― | -69.78% | -106.07% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.36B | -5.95 | -37.99% | ― | -27.15% | 23.10% |
* Healthcare Sector Average
LKFT
Lakefront Biotherapeutics
29.57
-4.35
-12.82%
NKTR
Nektar Therapeutics
39.84
-17.56
-30.59%
MESO
Mesoblast
14.27
-3.87
-21.33%
XNCR
Xencor
25.04
11.08
79.37%
ZYME
Zymeworks
25.33
7.22
39.87%
VIR
Vir Biotechnology
11.30
5.44
92.83%
Lakefront Biotherapeutics Corporate Events
Lakefront Biotherapeutics Buys Back 104K Shares in August Repurchase Tranche
Aug 12, 2026
Between August 3 and August 7, 2026, Lakefront Biotherapeutics repurchased 103,970 of its own shares under a buyback program first announced on June 9, 2026. The shares were acquired via an independent financial intermediary across several Europea...
Lakefront Biotherapeutics Posts First-Half 2026 Results, Closes Ouro Deal and Reaffirms €2B Cash Guidance
Aug 12, 2026
On August 10, 2026, Lakefront Biotherapeutics reported unaudited first-half 2026 results and detailed a strategic shift centered on immunology, highlighted by the June closing of its joint acquisition of Ouro Medicines with Gilead Sciences to co-d...
Lakefront Biotherapeutics Buys Back 98,648 Shares Under Ongoing Repurchase Program
Jul 21, 2026
On July 21, 2026, Lakefront Biotherapeutics reported that it had repurchased 98,648 of its own shares between July 13 and July 17, 2026, under a buyback program launched on June 9. The purchases, executed via an independent financial intermediary ...
Lakefront Biotherapeutics Board Member Resigns After Sanofi R&D Appointment
Jul 13, 2026
Lakefront Biotherapeutics, a Belgium-based biotechnology company listed on Euronext and Nasdaq, develops medicines for serious diseases in areas of high unmet need, with a clinical-stage focus on immunology and inflammation. Its lead asset, gamger...
Lakefront Biotherapeutics Buys Back Over 104,000 Shares Under June 2026 Repurchase Program
Jul 7, 2026
Between June 29 and July 3, 2026, Lakefront Biotherapeutics repurchased 104,022 of its ordinary shares under the share buyback program announced on June 9, 2026. The purchases were executed across multiple European trading venues at an average pri...
Lakefront Biotherapeutics Details June Share Buybacks Under Ongoing Repurchase Program
Jun 30, 2026
Between June 22 and June 26, 2026, Lakefront Biotherapeutics repurchased 83,530 of its ordinary shares on the Amsterdam exchange at an average price of €25.24 per share, for a total consideration of about €2.11 million. Following these...
Lakefront Biotherapeutics Discloses New 5% Stake by Madison Avenue Partners
Jun 30, 2026
On June 29, 2026, Lakefront Biotherapeutics reported that it had received a transparency notification under Belgian disclosure rules from Madison Avenue Partners and affiliated entities. The filing stated that Madison Avenue Partners crossed above...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.